Novartis notifies about Phase III COMBI-I study to treat skin cancer

By Nikita Chaurasia  | Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

WeWork India rectifies glitch that revealed visitors’ personal data

WeWork India rectifies glitch that revealed visitors’ personal data

By Nikita Chaurasia

WeWork Inc., a flexible workspace solutions company, has reportedly corrected a security flaw that gave unrestrained access to the personal details and selfies of several users who visited its coworking spaces. Sandeep Hodkasia, a security consult...

China’s Great Wall Motor suspends USD 1 Bn investment plan in India

China’s Great Wall Motor suspends USD 1 Bn investment plan in India

By Nikita Chaurasia

After failing to get regulatory permits, China's Great Wall Motor has reportedly abandoned its plans to invest USD 1 billion in India and has fired all employees from its Indian facilities. The Chinese automaker had planned to penetrate the India...

Walmart to double down on frictionless optical care with Memomi buyout

Walmart to double down on frictionless optical care with Memomi buyout

By Nikita Chaurasia

Walmart Inc. is reportedly planning to acquire the augmented reality optical tech firm Memomi, reflecting the retailer’s commitment to offering frictionless and omnichannel optical care. The buyout could potentially allow Walmart to offer a fun...

Google faces antitrust lawsuit from Danish job search entity Jobindex

Google faces antitrust lawsuit from Danish job search entity Jobindex

By Nikita Chaurasia

Google LLC was reportedly hit with an antitrust case by Jobindex, a Danish online job-search rival, that took its grievance to European regulators asserting that Alphabet Inc.’s subsidiary is unjustly favoring its job-search engine. The comp...

EU vows USD 630 Mn aid to vulnerable countries amidst Ukraine-conflict

EU vows USD 630 Mn aid to vulnerable countries amidst Ukraine-conflict

By Nikita Chaurasia

The European Union has reportedly pledged USD 630 million to support weaker nations to tackle food scarcity that was made worse by Russia's assault on Ukraine. The funds include USD 368 million in aid to increase long-term sustainable food produc...